161617-42-1

Basic information

• Product Name: Benzaldehyde, 2-amino-5-bromo-4-hydroxy-3-methoxy-
• CAS NO: 161617-42-1
• Molecular Formula: C8H8BrNO3
• Molecular Weight: 246.06
• Mol File: 161617-42-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 2-amino-5-bromo-4-hydroxy-3-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 2-amino-5-bromo-4-hydroxy-3-methoxy-(161617-42-1)
• EPA Substance Registry System: Benzaldehyde, 2-amino-5-bromo-4-hydroxy-3-methoxy-(161617-42-1)

Safety Data

• Hazardous Substances Data: 161617-42-1(Hazardous Substances Data)

Upstream product

• 2698-69-3 4-formyl-2-methoxy-3-nitrophenyl acetate 
• 881-68-5 vanillin acetate 
• 2450-26-2 2-nitrovanillin 
• 98434-34-5 5-bromo-4-hydroxy-3-methoxy-2-nitrobenzaldehyde 

Downstream Products

• 1415470-15-3 (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)benzo[d][1,3]dioxol-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

Synthesis of 1,2,3,9-tetrahydro-7-bromo-6-hydroxy-5-methoxypyrrolo-[2,1-b]- quinazol ine: A new analog of deoxyvasicine

A new deoxyvasicine analog (9) was synthesized by condensation of 2-amino-5-bromovanillin (6) with 4-aminobutyraldehyde (7) in phosphate buffer (pH 5.8) followed by hydrogenation of the resulting quinazolinium complex (8) at 65°C in presence of 5% palladium-on-barium sulfate.

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.